Parexel stretches out its site network to speed up enrollment

CRO giant Parexel International ($PRXL) has expanded its Rolodex of clinical trial sites to more than 180 around the world, a network the company says allows it to more quickly find patients for studies.

Recruitment can be one of the costliest factors in running a clinical trial, Parexel said, and difficulties in the process delay roughly 80% of studies by one to 6 months, according to the company.

That underscores the importance of having a wide span of sites from which to draw, Parexel said, and the company has been continually growing its network, now tapping more than 6,000 global investigators.

"Parexel has developed a strategic and relationship-driven approach to address one of the most critical challenges in the clinical trials journey--the patient enrollment process," Vice President Paul Evans said in a statement. "Through our site alliance network, we're better able to help pharmaceutical companies improve patient enrollment and accelerate the pace of clinical trials--making it possible to reduce time to market."

Meanwhile, Parexel has dimmed its expectations for fiscal 2015 after some disappointing sales and currency exchange hindrances. The CRO is expecting about $2 billion in fiscal 2015 revenue, a roughly 2% reduction from the $2.1 billion it forecast back in October.

- read the statement

Suggested Articles

WuXi AppTec has cut the ribbon on its expanded Laboratory Testing Division in New Jersey as it looks to boost its integrated testing service portfolio.

St. Jude, Microsoft and DNAnexus have created a data-sharing and analysis platform to help accelerate pediatric cancer research.

The money will be used to expand its footprint in both China and the U.S., including a new R&D operation in Boston.